Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)

Clinical Study of Neuspera's Implantable Sacral Nerve Stimulation (SNS) System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)

Prospective, multi-center, single-arm, seamless phase-pivotal study conducted in participants diagnosed with UUI who have failed or could not tolerate more conservative treatment. The trial will be conducted in two phases.

Objective of Phase I: To assess the utilization of the system during the Sacral Nerve Stimulation (SNS) trial period and to help inform the length of hours of daily stimulation to be used in Phase II of the trial.

Objective of Phase II: To assess the safety and efficacy of the Neuspera SNS System at 6-months for the primary efficacy endpoint and at 12 months for secondary safety and efficacy endpoints.

Study Overview

• Status: Active, not recruiting
• Conditions: Urinary Urgency Incontinence
• Intervention / Treatment: Device: Neuspera Implantable Sacral Nerve Stimulation System

Detailed Description

Neuspera's Implantable Sacral Nerve Stimulation (SNS) System is indicated to treat participants with UUI who have failed or could not tolerate more conservative treatments.

The study will be conducted in two phases: Phase I of the study will be conducted at up to 9 clinical study sites in the US and Europe. Phase II of the study will be conducted in up to 35 clinical sites in the US and Europe, inclusive of the Phase I centers.

Prospective, multi-center, single-arm, seamless phase-pivotal study. Objective of Phase I: To assess the utilization of the system during the Sacral Nerve Stimulation (SNS) trial period and to help inform the length of hours of daily stimulation to be used in Phase II of the trial.

Objective of Phase II: To assess the safety and efficacy of the Neuspera SNS System at 6-months for the primary efficacy endpoint and at 12 months for secondary safety and efficacy endpoints. All participants will receive the same length of device stimulation as determined in Phase I testing.

Phase I will enroll up to 55 participants. Phase II will enroll up to 255 participants.

• Study Type: Interventional
• Enrollment (Actual): 242
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Mark C Director of Clinical Research, BS; Phone Number: 408-433-3839; Email: mark.vollmer@neuspera.com
• Study Contact Backup: Name: Courtney Lane VP, Clinical Research and Regulatory Affairs, PhD; Phone Number: 805-856-8141; Email: courtney.lane@neuspera.com

Study Locations

• Belgium
  • Antwerp, Belgium
    • Universiteit Antwerpen
• Netherlands
  • Maastricht, Netherlands
    • Maastricht University Medical Center
  • Rotterdam, Netherlands
    • Erasmus University Medical Center
• United States
  • California
    • Encinitas, California, United States, 92024
      • Genesis Healthcare Partners
    • San Diego, California, United States, 92119
      • Kaiser Permanente
  • Florida
    • Pompano Beach, Florida, United States, 33060
      • Clinical Research Center of Florida
    • Tampa, Florida, United States, 33615
      • Florida Urology Partners, LLC
  • Georgia
    • Atlanta, Georgia, United States, 95816
      • Midtown Urology
  • Illinois
    • Lake Barrington, Illinois, United States, 60010
      • Comprehensive Urologic Care
  • Indiana
    • Fort Wayne, Indiana, United States, 46825
      • Women's Health Advantage
    • Indianapolis, Indiana, United States, 46202
      • Indiana University School of Medicine
  • Kansas
    • Kansas City, Kansas, United States, 66103-2937
      • University of Kansas Hospital
  • Kentucky
    • Louisville, Kentucky, United States, 40202
      • UofL Health System (University of Louisville)
  • Louisiana
    • New Orleans, Louisiana, United States, 70121
      • Ochsner Medical
  • Michigan
    • Wyoming, Michigan, United States, 49519
      • University of Michigan Health - West
  • Minnesota
    • Woodbury, Minnesota, United States, 55125
      • Minnesota Urology
  • Missouri
    • Saint Louis, Missouri, United States, 63141
      • Specialty Research of St. Louis
  • Nebraska
    • Omaha, Nebraska, United States, 68114
      • Adult & Pediatric Urology P.C.
  • New York
    • Poughkeepsie, New York, United States, 12603
      • Premier Medical Group
    • Syracuse, New York, United States, 13210
      • Associated Medical Professionals of Ny
  • Ohio
    • Cleveland, Ohio, United States, 44109
      • MetroHealth
  • Oregon
    • Portland, Oregon, United States, 97225
      • The Oregon Clinic Urogynecology West
  • Pennsylvania
    • North Wales, Pennsylvania, United States, 19454
      • The Institute for Female Pelvic Medicine and Reconstructive Surgery
  • South Carolina
    • Myrtle Beach, South Carolina, United States, 29572
      • Southern shores urogynecology
    • West Columbia, South Carolina, United States, 29169
      • Southern Urogynecology
  • Texas
    • Austin, Texas, United States, 78745
      • Urology Austin
    • Dallas, Texas, United States, 75231
      • Urology Clinics of North Texas (Dallas Center for Pelvic Medicine)
  • Washington
    • Seattle, Washington, United States, 98101
      • Virginia Mason
    • Seattle, Washington, United States, 98133
      • University of Washington

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 22 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Has a Body Mass Index (BMI) between 18 and 40.
2. Has a diagnosis of UUI for greater than or equal to 6 months prior to the screening baseline visit date.
3. Has failed or was not a candidate for more conservative treatment (e.g. pelvic floor training, biofeedback, behavioral modification).
4. Has failed or could not tolerate (stopped taking medication due to lack of efficacy or intolerable side effects) or not a good candidate for (as determined by treating physician) at least one (1) antimuscarinic or β3 adrenoceptor agonist medication.
5. Has a diagnosis of UUI with at least 4 UUI episodes on a 72-hour diary, and minimum of one (1) UUI episode per 24-hour period.

Exclusion Criteria:

1. Has a hemoglobin A1c of greater than 8 percent, or has diabetes mellitus with glucosuria.
2. Has diabetic neuropathy.
3. Has interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines, chronic pelvic pain or recurrent symptomatic urinary tract infections.
4. Has neurogenic bladder dysfunction such as traumatic or atraumatic myelopathy, multiple sclerosis, Parkinsonism, or history of cerebrovascular accident.
5. Has documented urinary retention within 6 months prior to the screening baseline visit date.
6. Has clinically significant bladder outlet obstruction.
7. Is a subject with a mechanical obstruction such as benign prostatic hypertrophy, urethral stricture or cancer.
8. Has primary stress incontinence or mixed incontinence where the stress component predominates or has been treated surgically for stress urinary incontinence within 6 months prior to the screening baseline visit date.
9. Has received tibial nerve stimulation (TNS) in the past 3 months for the treatment of overactive bladder or unwilling to stay off TNS therapy for 12-month period following implant.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Neuspera Implantable Sacral Nerve Stimulation System; Implantation of the simulator.	Device: Neuspera Implantable Sacral Nerve Stimulation System; Stimulation of the Sacral Nerve.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase II Primary Efficacy Endpoint: Defined as the percentage of participants who experience a 50 percent or more change in Urinary Urgency Incontinence episodes.	Change in Urinary Urgency Incontinence episodes at six months post-completion of the trial phase, relative to the number of Urinary Urgency Incontinence episodes at baseline prior to the trial phase.	Six months
Phase II Primary Safety Endpoint: Defined as the incidence of device-related serious adverse events in the post-trial period follow-up.	The number of serious adverse events related to the device.	Six months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase II Change in Quality of Life: Measured from baseline as measured and assessed by the total and subset International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life score.	Total score (25 min,160 max) with higher score indicating increase impact on quality of life.	6 and 12 months
Phase II Efficacy Endpoint: Defined as the percentage of participants who experience a 50 percent or more change in Urinary Urgency Incontinence.	Change in Urinary Urgency Incontinence episodes at 12 months post-completion of the trial phase, relative to the number of Urinary Urgency Incontinence episodes at baseline prior to the trial phase.	12 months
Phase II Comprehensive Summary of all Adverse Events	The incidence of adverse events will be reported.	6 and 12 months
Phase II Device Parameter Information Collected	Device amplitude will be collected in volts.	6 and 12 months
Phase II Physician and Subject User Experience Questionnaire	Physician and subject satisfaction will be obtained by answering questions on the use of the device using a five point scale:strongly agree, agree, neither agree nor disagree, disagree, strongly disagree. Answers towards strongly agree indicate a better outcome.	6 and 12 months
Phase II Urinary Tract Symptoms Questionnaire: International Consultation on Incontinence Questionnaire Female & Male Lower Urinary Tract Symptoms Modules	Change in male/female lower urinary tract symptoms questionnaire. Male questionnaire score ranges from 0-52 and female questionnaire score ranges from 0-48. Higher number indicates worse outcome.	6 and 12 months
Phase II Safety Endpoint: Defined as the incidence of device-related serious adverse events in the post-trial period follow-up.	The number of serious adverse events related to the device.	12 months
Phase II Urinary Output	Total urinary output as measured by 72-hour bladder diary.	6 and 12 months
Phase II Fecal Incontinence Measured by Wexner Scale	Fecal incontinence as measured by the Wexner Scale compared to baseline. Wexner scale total points 0-20, higher the score the worse the outcome.	6 and 12 months
Phase II Patient Global Impression of Improvement	Patient Global Impression of Improvement measured after implant during follow-up. Single question answered on a seven point scale: very much better, much better, a little better, no change, a little worse, much worse, very much worse. Selection of very much better is the best outcome.	6 and 12 months
Phase II Urgent Voids per Day	Change in urgent voids per day from baseline to 6-months and 12 months. Calculated across all diary episodes with at least mild urgency.	6 and 12 months
Phase !! Change in Average Number of Daily Voids	Change in average number of daily voids from baseline in subjects with at least 8 voids at baseline.	6 and 12 months

Collaborators and Investigators

• Sponsor: Neuspera Medical, Inc.

Publications and helpful links

Helpful Links

• Neuspera Medical web page

Study record dates

Study Major Dates

• Study Start (Actual): December 13, 2019
• Primary Completion (Estimated): July 1, 2024
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: December 9, 2019
• First Submitted That Met QC Criteria: January 14, 2020
• First Posted (Actual): January 18, 2020

Study Record Updates

• Last Update Posted (Actual): March 15, 2024
• Last Update Submitted That Met QC Criteria: March 12, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: UUI
• Other Study ID Numbers: Neuspera Medical (NSM)-004; SANS-UUI (Other Identifier: Neuspera)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: At this time, there is no plan to share information.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes